Why Is UNIQURE N V (QURE) Stock Down Today?

QURE stock is down 37.33% as of the close at $24.51 on concerns related to the durability of its Huntington’s disease therapy AMT-130. The four-year data from the Phase I/II study showed a smaller benefit compared to the three-year results, raising questions about the long-term efficacy of the treatment. This led to a sharp sell-off and triggered a broader market reaction, with several analysts and institutions revising their outlook.

What Happened

uniQure released updated data showing that AMT-130 continued to slow Huntington’s disease progression over four years in early- and mid-stage trials. However, the benefit was less than the three-year result, which had been a key pillar for its regulatory submission. Goldman Sachs lowered the price target for QURE to $31 from $46, while RBC and H.C. Wainwright described the data as mixed and questioned the durability of the treatment. The stock plummeted amid these developments, with PR Newswire and Stocktwits News highlighting the potential for a securities law investigation and the worst single-day drop in over 10 months. Meanwhile, Wells Fargo noted the stock weakness as an attractive opportunity, though the market remained bearish.

What The Data Shows

Over the last eight sessions, QURE has fallen 44.1% from $44.00 to $24.59. Recent insider transactions show three sales totaling $3.3 million, including by the CEO and the Chief Medical Officer. The stock hit two fresh 52-week lows and two 52-week highs on September 29. Options activity has been skewed to the downside, with put premiums totaling $341K compared to no call activity. The stock has a market cap of $2.7 billion, unprofitable with a TTM EPS of -4.04, and a beta of 0.94. Revenue increased 30.2% TTM.

What To Watch

The stock is currently trading near its 52-week low of $8.73. Investors should monitor the regulatory path for AMT-130 and any further updates from the FDA. Coverage breadth remains active, with 27 stories from 15 sources in the last 36 hours.